MarginsXMarginsX
Home › Markets › Health Care › IMVT

Immunovant Inc. (IMVT)

IMVT trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$33.28
-2.63% on the day
Market cap
$6.9B
Mid cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerIMVT on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2019
SEC CIK0001764013
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
21.9 months
$722.3M cash at September 30, 2026
Share count, 1 year
+18.1%
2025-11-03 to 2026-11-03 · +43.1% over 3 years
Going-concern doubt
No
10-Q filed November 9, 2026
Insider net buying, 12 months
$334.0M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-09
Cash and burn$722.3M cash; operating cash flow -$98.8M a quarter.Report 2026-09-30
Shares outstanding206,947,758 (2026-11-03); 175,276,526 a year earlier; 144,661,930 three years earlier.Cover page 2026-11-03
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2025-12-12
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Iselin, New Jersey, United StatesPCAOB Form AP 2026-06-04
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $350.0M, sold $16.0M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2027
2026-09-30
Not filed-$97.2M-$83.2M$722.3MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q1 2027
2026-06-30
Not filed-$153.2M-$124.4M$797.8MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q4 2026
2026-03-31
Not filed-$147.9M-$95.1M$902.1MNo debt tagsNeeds four quarters10-K 2026-05-20
Q3 2026
2025-12-31
Not filed-$110.6M-$92.3M$994.5MNo debt tagsNeeds four quarters10-Q 2026-02-06
Q2 2026
2025-09-30
Not filed-$126.5M-$102.5M$521.9MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q1 2026
2025-06-30
Not filed-$120.6M-$117.4M$598.9MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q4 2025
2025-03-31
Not filed-$106.4M-$110.6M$714.0MNo debt tagsNeeds four quarters10-K 2026-05-20
Q3 2025
2024-12-31
Not filed-$111.1M-$100.4M$374.7MNo debt tagsNeeds four quarters10-Q 2026-02-06

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2026-11-09
Latest annual report10-K2026-05-20
Latest quarterly / interim10-Q2026-11-09
Latest current report8-K2026-11-09
Latest proxyDEFA14A2026-07-22

Source: SEC EDGAR submissions feed, 653 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+12.0%
1 month+19.1%
3 months-18.3%
Year to date+34.5%
1 year+49.8%
From 52-week high-24.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
TWSTTwist Bioscience Corporation$105.04-5.88%$7.0B
KODKodiak Sciences Inc$100.73-9.41%$6.6B
IBRXImmunityBio Inc.$5.98-0.66%$6.4B
CGONCG Oncology Inc.$84.78+13.95%$7.6B
SRRKScholar Rock Holding Corporation$44.54+3.09%$5.4B
KRYSKrystal Biotech Inc.$297.90-2.40%$8.8B
PCVXVaxcyte Inc.$61.61-2.78%$9.8B
QGENQiagen N.V. Common Shares$49.81-0.16%$10.3B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier